


FORM PTO 1449 (modified)				ATTY DOCKET NO. <b>50454-56101USCIP3</b>		APPLICATION NO. <b>09/470,603</b>	
 <p style="margin-top: 10px;">U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)</p>				APPLICANT <b>Eugenio Cefali</b>			
				FILING DATE <b>31 October 1997</b>			GROUP <b>1615</b>
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
<b>OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
CH	1	<b>Expert Report of Cheryl D. Blume, Ph.D. (January 27, 2004)</b> - Subject to Protective Order					
	2	<b>Expert Report of Dr. Sergio Fazio (February 4, 2004) [Redacted Version]</b> - Subject to Protective Order					
	3	<b>Rebuttal Expert Report of Dr. Sergio Fazio (April 2, 2004)</b> - Subject to Protective Order					
	4	<b>Expert Report of Dr. Sergio Fazio Regarding U.S. Patent No. 6,676,967 (August 17, 2004)</b> - Subject to Protective Order					
	5	<b>Expert Report of Don W. Martens (February 6, 2004) [Redacted Version]</b> - Subject to Protective Order					
	6	<b>Expert Report of Don W. Martens Regarding U.S. Patent No. 6,676,967 (August 20, 2004) [Redacted Version]</b> - Subject to Protective Order					
	7	<b>Expert Report of Dr. Joseph R. Robinson (February 5, 2004) [Redacted Version]</b> - Subject to Protective Order					
	8	<b>Expert Report of Dr. Joseph R. Robinson Regarding U.S. Patent No. 6,676,967 (August 18, 2004)</b> - Subject to Protective Order					
V	9	<b>Rebuttal Expert Report of Thomas S. Foster, Pharm.D. (April 2, 2004)</b> - Subject to Protective Order					

Casey Hagopian 5-31-2005

CH	10	Rebuttal Expert Report of Thomas S. Foster, Pharm.D. Regarding The '967 Patent (October 4, 2004) - Subject to Protective Order
	11	Rebuttal Expert Report of James W. McGinity, Ph.D. (April 2, 2004) - Subject to Protective Order
	12	Supplemental Rebuttal Expert Report of James W. McGinity, Ph.D. (August 18, 2004) - Subject to Protective Order
	13	Rebuttal Expert Report of James W. McGinity, Ph.D. Regarding The '967 Patent (September 30, 2004) - Subject to Protective Order
	14	Expert Report of Mark E. McGovern, M.D. (February 6, 2004) - Subject to Protective Order
	15	Expert Report of Mark E. McGovern, M.D. (August 20, 2004) - Subject to Protective Order
	16	Expert Report of Frank M. Sacks, M.D. (April 2, 2004) - Subject to Protective Order
	17	Expert Report of Frank M. Sacks, M.D. (August 20, 2004) - Subject to Protective Order
	18	Rebuttal Expert Report of Mary Ann Tucker, Esq. (April 2, 2004) - Subject to Protective Order
	19	Rebuttal Expert Report of Mary Ann Tucker, Esq. Regarding The '967 Patent (October 1, 2004) - Subject to Protective Order
	20	Carl J. Lavie, et al., <i>Marked Benefit with Sustained-Release Niacin Therapy in Patients with Isolated@ Very Low Levels of High-Density Lipoprotein Cholesterol and Coronary Artery Disease</i> , Am. J. Cardiol. 1992;69:1083-1085
	21	Excerpts from the 1993, 2000, and 2002 editions of the Physician's Desk Reference
	22	<i>Niacin: Double-edged Sword for Lowering Cholesterol</i> , Tufts University Diet & Nutritional Letter (Tufts Univ., Boston, MA), August 1994, Vol. 12, issue 6
	23	Larsen, ML and Illingworth, DR, <i>Drug Treatment of Dyslipoproteinemia</i> , Med Clin N Am., 78:225-245 (1994)
✓	24	Lavie, Letter to Editor, JAMA 1994; 272:513-515

Casey Hagopian 5-31-2005

CH	25	Keenan, Letter to Editor, JAMA 1994; 272:513-515
	26	Shields & Beckmann, Letter to Editor, JAMA 1994; 272:513-515
	27	Thomas N. Tozer, Clinical Pharmacokinetics Concepts and Applications (3d ed. 1995) at Chapter 9, p. 120
	28	Excerpts from the United States Pharmacopela (1995)
	29	Morgan & Capuzzi Abstract, <i>Safe and Effective Treatment of Dyslipidemia by Niaspan, a New Sustained-Release Niacin</i> , Clinical Pharmacology & Therapeutics (February 1996)
	30	Morgan & Capuzzi Article, <i>Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial</i> , J. Cardiovasc. Pharmacol. Therapeut. 1(3):195-202 (July 1996)
	31	Capuzzi DM, et al., <i>Efficacy and Safety of An Extended-Release Niacin (Niaspan): A Long-Term Study</i> , Am J Cardiol. 1998;82:74U-81U
	32	Guyton JR, <i>Advances in Dyslipidemia: Discussion Session II</i> , Am J Cardiol, 1998: 82(12A): 85U-86U
	33	Knopp RH, et al., <i>Equivalent Efficacy of a Time-Release Form of Niacin (Niaspan) Given Once-a-Night Versus Plain Niacin in the Management of Hyperlipidemia</i> , Metabolism 47:1097-1104 (1998)
	34	American Diabetes Association: <i>Management of Dyslipidemia in Adults with Diabetes</i> , Diabetes Care 21:179-182, 1998
	35	Elam MB, et al., <i>Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease</i> , JAMA: 2000; 284:1263-1270
	36	Kesala R, et al., <i>Niacin (N) vs. Niaspan (NS) Treatment of the Atherogenic Lipid Profile (ALP; Small, Dense LDL, HDL2, HDLc and Triglycerides) and Lp(a) in Diabetic Patients (DP)</i> , Diabetes 49 (suppl. 1): A268 at 1114-P (June 2000)
	37	2001 NCEP Report at VI-11, Table VI.2-3
✓	38	Wang, W. et al., <i>Effect of Nicotinic Acid Administration on Hepatic Very Low Density Lipoprotein-Triglyceride Production</i> , Am J Physiol Endocrinol Metab., 280:E540-E547 (2001)

Casey Haggren 5-31-2005

CH	39	Smith SC, et al., <i>AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients with Atherosclerotic Cardiovascular Disease: 2001 Update</i> . AHA/ACC Scientific Statement, 1577-79
	40	Tavintharan S and Kashyap M, <i>The Benefits of Niacin in Atherosclerosis</i> , Curr Athero. Reports 2001; 3:74-82
	41	Meadows M., <i>Serious Liver Injury: Leading Reason for Drug Removals, Restrictions</i> , FDA Consumer Magazine, May-June 2001; <a href="http://www.fda.gov/fdac/features/2001/301_liver.html">http://www.fda.gov/fdac/features/2001/301_liver.html</a>
	42	Grundy SM, et al., <i>Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated with Type 2 Diabetes</i> . Arch Intern Med. 2002; 162: 1568-1576
	43	American Diabetes Association: <i>Management of Dyslipidemia in Adults with Diabetes</i> , Diabetes Care 25:S74-S77, 2002
	44	Pan J, et al., <i>Niacin Treatment of the Atherogenic Lipid Profile and Lp(a) in Diabetes</i> , Diabetes, Obesity and Metabolism 4:255-261 (2002)
	45	Pan J, et al., <i>Extended-Release Niacin Treatment of the Atherogenic Lipid Profile and Lipoprotein(a) in Diabetes</i> , Metabolism 51:1120-1127 (2002)
	46	Meyers CD, et al., <i>Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia</i> , Ann Intern Med. 2003; 139:996-1002
	47	CDER <i>Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations</i> (March 2003)
	48	American Diabetes Association: <i>Dyslipidemia Management in Adults with Diabetes</i> , Diabetes Care 27:S68-S71, 2004
	49	<del>Sample Kos Clinical Trial Medical Consent Form</del> <del>- Subject to Protective Order</del>
✓	50	<del>Sample Kos Clinical Trial Investigator's Statement</del> <del>- Subject to Protective Order</del>
EXAMINER <i>Valery Haggopian</i>		DATE CONSIDERED <i>5-31-2005</i>